Abstract
Two N-aralkylated (N-benzyl-and N-alpha-methylbenzyl-) derivatives of 1-aminobenzotriazole, a mechanism-based inhibitor of cytochrome P450 with low isozyme selectivity, were previously shown to be potent and isozyme-selective suicide substrates for rabbit and guinea pig pulmonary P450 in vitro (Mathews and Bend, 1986; Woodcroft et al., 1990). These three compounds were compared as inhibitors in vivo after i.v. administration to rabbits treated with the cytochrome P450 inducers beta-naphthoflavone or phenobarbital. By 1 hr after administration of N-alpha-methylbenzyl-1-aminobenzotriazole (1 mumol/kg), 80% of P450 2Bs-catalyzed benzphetamine N-demethylation in lung of beta-naphthoflavone-treated rabbits was inactivated and about 35% of P450 was lost without inhibition of P450 1A1-catalyzed activity; at a dose of 10 or 100 mumol/kg, this compound totally inactivated pulmonary P450 2Bs activity while exerting minimal effects on benzphetamine N-demethylation activity (< 20% inhibition) in liver of beta-naphthoflavone-treated rabbits. N-benzyl-1-aminobenzotriazole was also an isozyme- and tissue-selective inhibitor of pulmonary P450 2Bs in vivo. Relatively high doses (100 mumol/kg) of these compounds were compared in phenobarbital-induced rabbits. Virtually all (> or = 95%) of pulmonary P450 2Bs-dependent activity was inhibited by the two N-aralkylated compounds (vs. 50% for 1-aminobenzotriazole). At this dose, about 25% of hepatic P450 was destroyed by all three compounds, whereas 1-aminobenzotriazole and its N-benzyl and N-alpha-methylbenzyl derivatives inactivated 20, 50 and 85% of hepatic P450 2Bs-selective benzphetamine N-demethylation activity, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|